Advances in the management of constipation-predominant irritable bowel syndrome: The role of linaclotide

Siegfried W.B. Yu, Satish S.C. Rao

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Constipation-predominant irritable bowel syndrome (IBS-C) is a commonly prevalent and clinically challenging disorder to treat. Until recently, most therapeutic agents had limited ability to address the complexity of symptoms inherent to the syndrome. The development of linaclotide provides a physiologically sound approach to treatment of the multiple symptoms of IBS-C. Clinical trials demonstrate the efficacy of linaclotide, and a platform to better understand the symptomatology of IBS-C. Based on recent clinical evidence, linaclotide should be considered for patients with IBS-C because it improves abdominal pain and bowel symptoms. In phase III trials, linaclotide met the US Food and Drug Administration responder endpoint with a number needed to treat (NNT) of 5.1–7.9, and European Medicines Agency coprimary endpoints at 12 weeks with a NNT of 4.39–7.69, and at 26 weeks with a NNT of 4.93–5.68. It is safe and effective, with diarrhea reported as the most common adverse effect, which leads to discontinuation of the medication in approximately 5% of patients.

Original languageEnglish (US)
Pages (from-to)193-205
Number of pages13
JournalTherapeutic Advances in Gastroenterology
Issue number5
StatePublished - Sep 2014


  • IBS-C
  • constipation
  • irritable bowel syndrome
  • linaclotide

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Advances in the management of constipation-predominant irritable bowel syndrome: The role of linaclotide'. Together they form a unique fingerprint.

Cite this